A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells

References

• Mangan JK, Speck NA. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog. 2011;16:77–91.
   PubMedGoogle Scholar
• Lam K, Zhang DE. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed). 2012;17:1120–1139.
   PubMed Web of Science ®Google Scholar
• Cai Z, de Bruijn MFTR, Ma X, et al. Haploinsufficiency of AML1/CBFA2 affects the embryonic generation of mouse hematopoietic stem cells. Immunity. 2000;13:423–431.
   PubMed Web of Science ®Google Scholar
• Cai X, Gaudet JJ, Mangan JK, et al. Runx1 loss minimally impacts long-term hematopoietic stem cells. PLoS One. 2011;6:e28430.
   PubMed Web of Science ®Google Scholar
• Motoda L, Osato M, Yamashita N, et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells. 2007;25:2976–2986.
   PubMed Web of Science ®Google Scholar
• Jacob B, Osato M, Yamashita N, et al. Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood. 2010;115;1610–1620.
   PubMed Web of Science ®Google Scholar
• Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106:494–504.
   PubMed Web of Science ®Google Scholar
• Putz G, Rosner A, Nuesslein I, et al. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene. 2006;25:929–939.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320.
   PubMed Web of Science ®Google Scholar
• Gulley ML, Shea TC, Fedoriw Y. Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn. 2010;12:3–16.
   PubMed Web of Science ®Google Scholar
• Duployez N, Willekens C, Marceau-Renaut A, et al. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Exp Rev Hematol. 2015;8:43–56.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheney MD, Gaudet JJ, et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell. 2006;9:249–260.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen W, Gaudet J, et al. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell. 2007;11:483–497.
   PubMed Web of Science ®Google Scholar
• Corpora T, Roudaia L, Oo ZM, et al. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity. J Mol Biol. 2010;402:560–577.
   PubMed Web of Science ®Google Scholar
• Park S, Chen W, Cierpicki T, et al. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. Blood. 2009;113:3558–3567.
   PubMed Web of Science ®Google Scholar
• Roudaia L, Cheney MD, Manuylova E, et al. CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood. 2009;113:3070–3079.
   PubMed Web of Science ®Google Scholar
• Sun XJ, Wang Z, Wang L, et al. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature. 2013;500:93–97.
   PubMed Web of Science ®Google Scholar
• Wei Y, Liu S, Lausen J, et al. A TAF4-homology domain from the corepressor ETO is a docking platform for positive and negative regulators of transcription. Nat Struct Mol Biol. 2007;14:653–661.
   PubMed Web of Science ®Google Scholar
• Bravo J, Li Z, Speck NA, et al. The leukaemia-associated AML1 (Runx1)-CBFb complex functions as a DNA-induced molecular clamp. Nat Struct Biol. 2001;8:371–377.
   PubMedGoogle Scholar
• Tahirov TH, Inoue-Bungo T, Morii H, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFb. Cell. 2001;104:755–767.
   PubMed Web of Science ®Google Scholar
• DeKelver RC, Yan M, Ahn EY, et al. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood. 2013;121:3714–3717.
   PubMed Web of Science ®Google Scholar
• Kwok C, Zeisig BB, Qiu J, et al. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci USA. 2009;106:2853–2858.
   PubMed Web of Science ®Google Scholar
• Ben-Ami O, Friedman D, Leshkowitz D, et al. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep. 2013;4:1131–1143.
   PubMed Web of Science ®Google Scholar
• Goyama S, Schibler J, Cunningham L, et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest. 2013;123:3876–3888.
   PubMed Web of Science ®Google Scholar
• Choi A, Illendula A, Pulikkan JA, et al. RUNX1 is required for oncogenic Myb and Myc enhancer activity in T cell acute lymphoblastic leukemia. Blood. 2017;130:1722–1733.
   PubMed Web of Science ®Google Scholar
• Young DW, Hassan MQ, Pratap J, et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature. 2007;445:442–446.
   PubMed Web of Science ®Google Scholar
• Teplyuk NM, Zhang Y, Lou Y, et al. The osteogenic transcription factor runx2 controls genes involved in sterol/steroid metabolism, including CYP11A1 in osteoblasts. Mol Endocrinol. 2009;23:849–861.
   PubMed Web of Science ®Google Scholar
• Gorczynski MJ, Grembecka J, Zhou Y, et al. Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol. 2007;14:1186–1197.
   PubMed Web of Science ®Google Scholar
• Illendula A, Pulikkan JA, Zong H, et al. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFbeta-SMMHC delays leukemia in mice. Science. 2015;347:779–784.
   PubMed Web of Science ®Google Scholar
• Illendula A, Gilmour J, Grembecka J, et al. Small molecule inhibitor of CBFbeta-RUNX binding for RUNX transcription factor driven cancers. EBioMed. 2016;8:117–131.
   PubMed Web of Science ®Google Scholar
• Lin HF, Traver D, Zhu H, et al. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood. 2005;106:3803–3810.
   PubMed Web of Science ®Google Scholar
• North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447:1007–1011.
   PubMed Web of Science ®Google Scholar
• Carroll KJ, Esain V, Garnaas MK, et al. Estrogen defines the dorsal-ventral limit of VEGF regulation to specify the location of the hemogenic endothelial niche. Dev Cell. 2014;29:437–453.
   PubMed Web of Science ®Google Scholar
• Li L, Jin H, Xu J, et al. Irf8 regulates macrophage versus neutrophil fate during zebrafish primitive myelopoiesis. Blood. 2011;117:1359–1369.
   PubMed Web of Science ®Google Scholar
• Bohm HJ. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des. 1992;6:61–78.
   PubMed Web of Science ®Google Scholar
• Bohm HJ. On the use of LUDI to search the fine chemicals directory for ligands of proteins of known three-dimensional structure. J Comput Aided Mol Des. 1994;8:623–632.
   PubMed Web of Science ®Google Scholar
• Perez-Alvarado GC, Munnerlyn A, Dyson HJ, et al. Identification of the regions involved in DNA binding by the mouse PEBP2alpha protein. FEBS Lett. 2000;470:125–130.
   PubMed Web of Science ®Google Scholar
• Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc. 2001;123:6108–6117.
   PubMed Web of Science ®Google Scholar
• Mayer M, Mayer B. Characterization of ligand binding by saturaton transfer difference NMR spectroscopy. Angew Chem Int Ed. 1999;38:1784–1788.
   PubMed Web of Science ®Google Scholar
• Li P, Shi L, Gao MN, et al. Antibacterial activities against rice bacterial leaf blight and tomato bacterial wilt of 2-mercapto-5-substituted-1,3,4-oxadiazole/thiadiazole derivatives. Bioorg Med Chem Lett. 2015;25:481–484.
   PubMed Web of Science ®Google Scholar
• North TE, Goessling W, Peeters M, et al. Hematopoietic stem cell development is dependent on blood flow. Cell. 2009;137:736–748.
   PubMed Web of Science ®Google Scholar
• Cunningham L, Finckbeiner S, Hyde RK, et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFbeta interaction. Proc Natl Acad Sci USA. 2012;109:14592–14597.
   PubMed Web of Science ®Google Scholar
• Kalev-Zhylinska M, Horsfield JA, Flores MVC, et al. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis. Development. 2002;129:2015–2030.
   PubMed Web of Science ®Google Scholar
• Matheny CJ, Speck ME, Cushing PR, et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. Embo J. 2007;26:1163–1175.
   PubMed Web of Science ®Google Scholar
• North TE, Gu T-L, Stacy T, et al. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development. 1999;126:2563–2575.
   PubMed Web of Science ®Google Scholar
• Murayama E, Kissa K, Zapata A, et al. Tracing hematopoietic precursor migration to successive hematopoietic organs during zebrafish development. Immunity. 2006;25:963–975.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511:616–620.
   PubMed Web of Science ®Google Scholar
• Cullion K, Draheim KM, Hermance N, et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood. 2009;113:6172–6181.
   PubMed Web of Science ®Google Scholar
• Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199–207.
   PubMed Web of Science ®Google Scholar
• Zuber J, Radtke I, Pardee TS, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009;23:877–889.
   PubMed Web of Science ®Google Scholar
• Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med. 2006;12:945–949.
   PubMed Web of Science ®Google Scholar
• Teplyuk NM, Galindo M, Teplyuk VI, et al. Runx2 regulates G protein-coupled signaling pathways to control growth of osteoblast progenitors. J Biol Chem. 2008;283:27585–27597.
   PubMed Web of Science ®Google Scholar
• Cai X, Gao L, Teng L, et al. Runx1 deficiency decreases ribosome biogenesis and confers stress resistance to hematopoietic stem and progenitor cells. Cell Stem Cell. 2015;17:165–177.
   PubMed Web of Science ®Google Scholar
• Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell. 2010;7:532–544.
   PubMed Web of Science ®Google Scholar
• Hoogenkamp M, Lichtinger M, Krysinska H, et al. Early chromatin unfolding by RUNX1 - a molecular explanation for differential requirements during specification versus maintenance of the hematopoietic gene expression program. Blood. 2009;114:299–309.
   PubMed Web of Science ®Google Scholar
• Frye SV. The art of the chemical probe. Nat Chem Biol. 2010;6:159–161.
   PubMed Web of Science ®Google Scholar
• Sanda T, Lawton LN, Barrasa MI, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012;22:209–221.
   PubMed Web of Science ®Google Scholar
• Mansour MR, Abraham BJ, Anders L, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014;346:1373–1377.
   PubMed Web of Science ®Google Scholar
• Scheitz CJ, Lee TS, McDermitt DJ, et al. Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. Embo J. 2012;31:4124–4139.
   PubMed Web of Science ®Google Scholar
• Scheitz CJ, Tumbar T. New insights into the role of Runx1 in epithelial stem cell biology and pathology. J Cell Biochem. 2013;114:985–993.
   PubMed Web of Science ®Google Scholar
• Morita K, Suzuki K, Maeda S, et al. Genetic regulation of the RUNX transcription factor family has antitumor effects. J Clin Investig. 2017;127:2815–2828.
   PubMed Web of Science ®Google Scholar